Rarely, an allergic reaction (rash, throat tightness) can occur
Medicare Part D is statutorily prohibited from covering medications when used for weight loss. This prohibition, enacted as part of the Medicare Modernization Act of 2003, has become increasingly contentious as the evidence base for GLP-1 agonists in obesity has strengthened
A diabetes pill is not interchangeable with the obesity pill, and doctors will not swap them on a milligram-for-milligram basis
This explosion in demand led to a shortage in GLP-1 supply, starting with semaglutide, the key ingredient in Wegovy, in March 2022
Weight regain is the likely outcome with both compounds
As it gained attention for its effectiveness, GLP-1 shots earned FDA approval for weight management in adults and children over the age of 12 with or without diabetes